---
title: "Stryker | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 6.589 B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294410562.md"
datetime: "2026-07-30T20:20:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294410562.md)
  - [en](https://longbridge.com/en/news/294410562.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294410562.md)
generator: "portal-rs"
---

# Stryker | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 6.589 B

Revenue: As of FY2026 Q2, the actual value is USD 6.589 B, beating the estimate of USD 6.579 B.

EPS: As of FY2026 Q2, the actual value is USD 3.3, beating the estimate of USD 2.9653.

EBIT: As of FY2026 Q2, the actual value is USD 1.564 B.

The provided reference, a Form 8-K filing by Stryker Corporation, indicates the issuance of a press release on July 30, 2026, announcing its second-quarter 2026 operating results. However, the Form 8-K itself does not contain detailed financial or operational metrics, segment revenues, cash flow data, or specific outlook/guidance information. These details are contained in the referenced Exhibit 99.1, which is the press release itself and is not provided in the reference text. Consequently, no specific financial or operational metrics can be extracted from the given content.

### Related Stocks

- [SYK.US](https://longbridge.com/en/quote/SYK.US.md)

## Related News & Research

- [Stryker Corporation $SYK Shares Sold by Hollencrest Capital Management](https://longbridge.com/en/news/297422828.md)
- [Stryker Corporation $SYK Shares Sold by NS Partners Ltd](https://longbridge.com/en/news/297632775.md)
- [Stryker agrees to acquire rotator cuff augmentation developer ZuriMED](https://longbridge.com/en/news/297556265.md)
- [Stryker Insider Makes Bold New Move With Fresh Share Purchase](https://longbridge.com/en/news/297854839.md)
- [Stryker director Mary K. Brainerd reports $4,120.75 common share purchase](https://longbridge.com/en/news/297824280.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**